Table 1.
Patient demographic and dabigatran dosing characteristics
| Characteristic | Value |
|---|---|
| Mean Age ± SD (years) | 81.3 ± 4.5 |
| Female (%) | 44.5 |
| Mean time after last dabigatran dose ± SD (hours) | 13.1 ± 2.3 |
| Mean weight ± SD (kg) | 83.0 ± 21.1 |
| Body mass index ± SD (kg/m2) | 28.9 ± 4.7 |
| Baseline Renal Clearance ± SD (mL/min) | |
| Cockcroft-Gault | 68.4 ± 28.4 |
| CKD-EPI | 40.9 ± 12.3 |
| Dabigatran dosage, n (%) | |
| 75 mg twice daily | 4 (44.4) |
| 150 mg twice daily | 5 (55.6) |
| Cormorbidities (n, %) | |
| Chronic obstructive pulmonary disease | 3 (33.3) |
| Diabetes Mellitus | 4 (44.4) |
| Heart Failure | 3 (33.3) |
| Malignancy | 2 (22.2) |
| Thyroid Disease | 4 (44.4) |
| Coronary Artery Disease | 2 (22.2) |
| Mean HPLC-MS/MS dabigatran level ± SD (ng/mL)a | 161.1 ± 104.1 |
| Mean chromogenic anti-IIa dabigatran level ± SD (ng/mL)a | 161.9 ± 104.8 |
aPooled data from all office visits